CN Patent
CN106467496B — 4-[(5,6-二苯基哌嗪-2-基)(异丙基)胺基]-1-丁醇的制备方法
Assigned to Suzhou Guokuang Pharmaceutical Technology Co ltd · Expires 2020-12-08 · 5y expired
What this patent protects
本发明公开了一种4‑[(5,6‑二苯基哌嗪‑2‑基)(异丙基)胺基]‑1‑丁醇的制备方法,将式3化合物与4‑(异丙氨基)丁醇在碱性或中性条件中混合,在较温和的反应温度下得到式1化合物。
USPTO Abstract
本发明公开了一种4‑[(5,6‑二苯基哌嗪‑2‑基)(异丙基)胺基]‑1‑丁醇的制备方法,将式3化合物与4‑(异丙氨基)丁醇在碱性或中性条件中混合,在较温和的反应温度下得到式1化合物。
Drugs covered by this patent
- Uptravi (SELEXIPAG) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.